Literature DB >> 33184712

Exploring advance care planning awareness, experiences, and preferences of people with cancer and support people: an Australian online cross-sectional study.

Helena Rodi1, Karen Detering2,3, Marcus Sellars2,4, Ashley Macleod2, Julia Todd2, Sonia Fullerton5, Amy Waller6, Linda Nolte2.   

Abstract

PURPOSE: To explore advance care planning (ACP) awareness, experiences, and preferences of people with cancer and support people of someone with cancer, in Australia.
METHODS: Descriptive analysis and independent group t tests were used to examine data from a national, online cross-sectional survey.
RESULTS: Of 705 respondents (440 people with cancer, 265 support people), 48.5% of participants had heard of ACP prior to the survey and 65% had discussed their values or preferences with someone. Significantly more people aged under 65 years had discussed their preferences than their older counterparts. Most (93%) discussions occurred with family or friends, but only 3.7% occurred with a health professional. A total of 33% had documented their preferences, with support people, women, and people aged under 65 years significantly more likely to have signed a legal document appointing someone to make medical decisions on their behalf. Views varied about the preferred timing of ACP and end-of-life care discussions (38.3% when cancer is incurable compared to 20% at diagnosis). Only 3.0% did not want to discuss ACP at all. Topics discussed were significantly different based on cohort, gender, age group, treatment status, and region.
CONCLUSION: Despite increasing community awareness of ACP, understanding remains low amongst cancer patients and support people, who generally rely on discussions with family and friends rather than health professionals. ACP should be introduced early across multiple interactions with health professionals, discuss a broad range of ACP relevant topics, and involve the cancer patient and their support person.

Entities:  

Keywords:  Advance care directive; Advance care planning; Caregiver; End-of-life care; Oncology; Survey

Year:  2020        PMID: 33184712     DOI: 10.1007/s00520-020-05878-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  3 in total

1.  Prevalence and predictors of advance directives in Australia.

Authors:  B White; C Tilse; J Wilson; L Rosenman; T Strub; R Feeney; W Silvester
Journal:  Intern Med J       Date:  2014-10       Impact factor: 2.048

2.  Does implementation matter if comprehension is lacking? A qualitative investigation into perceptions of advance care planning in people with cancer.

Authors:  Anna Ugalde; Clare O'Callaghan; Clem Byard; Samantha Brean; Jenelle MacKay; Anna Boltong; Sondra Davoren; Deborah Lawson; Phillip Parente; Natasha Michael; Patricia Livingston
Journal:  Support Care Cancer       Date:  2018-05-11       Impact factor: 3.603

3.  Medical oncology outpatients' preferences and experiences with advanced care planning: a cross-sectional study.

Authors:  Amy Waller; Heidi Turon; Jamie Bryant; Alison Zucca; Tiffany-Jane Evans; Rob Sanson-Fisher
Journal:  BMC Cancer       Date:  2019-01-14       Impact factor: 4.430

  3 in total
  3 in total

Review 1.  A model for the uptake of advance care planning in older cancer adults: a scoping review.

Authors:  Yiping Chen; Liyuan Hou; Xianhui Zhang; Yifei Du; Xiaoqing Zhang; Min Li; Chaoyue Gao; Hui Yang
Journal:  Aging Clin Exp Res       Date:  2022-07-26       Impact factor: 4.481

Review 2.  Older patients' and their caregivers' understanding of advanced care planning.

Authors:  Elissa Kozlov; Danielle H Llaneza; Kelly Trevino
Journal:  Curr Opin Support Palliat Care       Date:  2022-03-01       Impact factor: 2.265

3.  Advance care planning participation by people with dementia: a cross-sectional survey and medical record audit.

Authors:  Jamie Bryant; Marcus Sellars; Amy Waller; Karen Detering; Craig Sinclair; Rasa Ruseckaite; Ben White; Linda Nolte
Journal:  BMJ Support Palliat Care       Date:  2021-03-03       Impact factor: 4.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.